Shine-On BioMedical (6926) Fundamentals 2026 — Revenue Analysis | SniperIQ
Shine-On BioMedical (6926) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT
Shine-On BioMedical (6926) has a market capitalization of approximately NT
Shine-On BioMedical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Shine-On BioMedical runs a net profit margin of -367.6%, a gross margin of 93.1%, and an operating margin of -418.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Shine-On BioMedical reported revenue of NT
Shine-On BioMedical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Shine-On BioMedical carries a debt-to-equity ratio of 0.00x and a current ratio of 21.48x, with a market beta of -0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shine-On BioMedical (6926) the key facts are: market cap NT
Get Shine-On BioMedical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.